High-dose chemotherapy and stem cell rescue is increasingly being delivered in the outpatient setting. Such intensive outpatient management programs have reduced the total hospital length of stay without compromising clinical outcomes. However, a detailed financial analysis of outpatient programs has not been performed. These data are the results of a prospective study of 94 patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant in one of three settings: traditional inpatient, partial outpatient, total outpatient. Patients were allowed to choose their own treatment setting based upon the availability of a caregiver and personal preference. Total hospital length of stay and the actual cost and charges for each patient were monitored prospectively. The patients in the three groups were well balanced with regard to age and functional status prior to high-dose chemotherapy. The average length of stay was reduced from 17.3 to 8.2 to 2.7 days in the three different treatment settings (P Ͻ 0.01). Mean procedure costs were reduced from $39.7 thousand (US dollars) to $36.2 thousand to $29.4 thousand in the three treatment settings (P Ͻ 0.029). No differences in toxicity or overall response to therapy was noted. High-dose chemotherapy and stem cell rescue can be safely administered in the outpatient setting and results in significant cost savings.
1
Among the reasons for the high costs of HDC/ASCR is the prolonged hospitalization traditionally required for this treatment. Even with the use of hematopoietic growth factors and mobilized blood progenitor cells, which have shortened neutropenia and allowed earlier hospital discharge, hospital stays of 16 to more than 30 days are typical. 2, 3, 4 Peters and colleagues, 5 at Duke University Medical Center, pioneered a structured outpatient bone marrow transplant program wherein patients received all their highdose chemotherapy as inpatients and then were discharged to a 7-day-a-week outpatient clinic located a short distance from the main hospital. These patients had stage 2-4 breast cancer and received a high-dose chemotherapy regimen which did not induce a significant rate of mucositis, esophagitis or enteritis. In that program, all outpatients were housed in a local hotel adjacent to the outpatient clinic. In 1993, the Scripps Clinic stem cell transplant program advanced this model to include patients with diseases other than breast cancer receiving other chemotherapy regimens with a higher incidence of mucositis. 6 Subsequently we developed a 'total outpatient transplant' (TOT) model in which all the high-dose chemotherapy as well as the supportive care was given in the outpatient setting. This method of delivery of care significantly reduced the hospital length of stay. 7 The current study is a financial analysis of hospital and clinic charges and costs associated with the high-dose chemotherapy procedure given in three different settings: inpatient hospital, inpatient chemotherapy with outpatient follow-up (subtotal outpatient) and outpatient chemotherapy with outpatient follow-up (total outpatient transplantation).
Patients and methods
Ninety-four consecutive patients receiving HDC/ASCR with one of two different chemotherapy regimens were studied over an 18-month period. Patients were assigned to one of the three treatment settings based upon the presence of a caregiver and personal preference. No patient was excluded from the outpatient programs because of pretreatment performance status. Patients in the 'inpatient' model received all their chemotherapy in the hospital, as well as reinfusion of stem cells and supportive care until there was sufficient neutrophil and platelet engraftment and resolution of other toxicities to allow outpatient follow-up. Patients receiving treatment in the 'subtotal outpatient transplant' (STOT) program received 4 days of high-dose chemotherapy in the hospital. These patients were discharged to a 7-day-a-week outpatient clinic the day after completion of chemotherapy or as soon as clinically stable.
In the total outpatient transplant program patients received all their chemotherapy in the outpatient setting as well as supportive care. Patients received pre-hydration and antiemetics followed by chemotherapy administered via a 4-h infusion into a central venous catheter daily for 4 days. This procedure was performed in the outpatient department from which patients were discharged to either their private home or a local hotel. The study was not randomized, patients being allowed to choose the site of their therapy. To look for potential selection bias we examined both pretreatment characteristics and treatment-related toxicities of patients in the three groups.
Supportive care
Patients treated in either the sub-total or total outpatient programs were required to have a 'caregiver' present to help monitor oral intake, urine output and temperature, and to record oral medication use. Outpatients were instructed to keep a diary of fluid intake and output, temperature log, and a list of oral medications self-administered. Patients were seen daily by transplant nurses and physicians and had chemistry and hematology assessments performed. Fluid and/or electrolyte supplementation, transfusions and intravenous antibiotics were administered in the outpatient setting utilizing ambulatory pumps when necessary. Home health agencies were not utilized. Patients remained in the outpatient clinic for 1-6 h, depending on their requirements for the day, and then were discharged to either their own home or to local motels or apartments arranged by the transplant program. These local accommodations were not modified in any way.
Patients were instructed on infection control measures pertaining to personal hygiene, diet and exposure to microorganisms. Prophylactic antibiotics consisting of ciprofloxacin 500 mg and rifampin 300 g each p.o. twice a day were administered to all patients regardless of treatment setting. 8 In both outpatient transplant programs, specific criteria for re-admission were utilized including uncontrolled emesis, nausea, diarrhea, rapidly rising creatinine or unstable hemodynamics. Febrile neutropenia was not an indication for immediate re-admission unless complicated by other organ toxicities such as hypotension, renal insufficiency, etc.
Chemotherapy regimens
The chemotherapy doses and schedule were identical in all three treatment settings. Cyclophosphamide 6000 mg/m 2 , thiotepa 500 mg/m 2 and carboplatin 1200 mg/m 2 , in divided doses over 4 days, was given to patients with breast or ovarian cancer. Patients with lymphoma had etoposide 1800 mg/m 2 substituted for thiotepa. Each day's chemotherapy was infused over 4 h. Previously mobilized and cryopreserved peripheral blood progenitor cells were infused 48 h after the completion of chemotherapy. Granulocyte colony-stimulating factor (G-CSF) 5 g/kg was administered subcutaneously beginning on the day of peripheral blood progenitor cell reinfusion and continued until the absolute neutrophil count was Ͼ2000 mm 3 .
Financial analysis
Hospital and clinic computerized patient charts and financial records were used to collect all charges related to the high-dose chemotherapy and autologous stem cell rescue procedure, beginning with the first day of chemotherapy and continuing until 30 days after stem cell infusion unless still under care for transplant-related complications. Excluded from this analysis, therefore, were all charges related to induction chemotherapy, if any, and pre-transplant evaluation such as radiographic studies, blood tests and baseline physiologic assessments. The actual medical record was cross-checked against the computerized billing record to ensure accuracy. Because some patients were able to fill low-cost prescriptions for G-CSF from low-cost suppliers for use after re-infusion of progenitor cells, these costs were standardized for the entire patient population using outpatient pharmacy charges for the appropriate dose of G-CSF. Similarly, since some patients had central venous catheters inserted at other institutions, the cost for the insertion of the central venous catheter was standardized based upon typical institutional charges for operating room time, anesthesia and the catheter itself. During the period of this study, the location of the blood progenitor cell apheresis and cryopreservation changed from an outside commercial blood bank to an internal cryopreservation facility. Because these two locations had different charges associated with stem cell preparation, all charges for leukapheresis and cryopreservation of progenitor cells were standardized assuming adequate collection in a single procedure, which has been recently demonstrated. 9, 10 Thus the charges and costs reported include standardized costs for mobilization of blood progenitor cells, leukapheresis, cryopreservation and central venous catheter insertion.
Inpatients were charged a special bone marrow transplant room rate for the first 4 days of hospitalization which took into account a low patient-to-nurse ratio. Thereafter, patients who remained hospitalized were billed at standard hospital room rates. Patients who had Intensive Care Unit stays were billed at the standard room rate for that unit.
The outpatient clinic was located within the inpatient stem cell therapy ward. Patients evaluated there were charged on a sliding scale basis assigned by the treating nurse based upon the complexity of their care for that day. There were five levels of charges reflecting five levels of care from lowest complexity to highest complexity. Other charges, (pharmacy, blood bank, radiology, laboratory and physician fees) were based on actual utilization of individual patients.
Those patients participating in the outpatient transplant programs who resided in local hotels or apartments (64% of outpatients) had the cost of their housing assigned to their outpatient bills unless they resided at their own resi-929 dence. Patient meals taken during times they were in the outpatient clinic were charged to their outpatient bills.
This study did not attempt to account for out-of-pocket expenses of either the patients or their caregivers or for lost wages or vacation time.
An estimate of actual costs was obtained by grouping the charges into cost center categories such as pharmacy, blood bank and laboratory, and then multiplying each group by the institution-specific ratio of costs to charges supplied to Medicare for all hospital-based activities. Professional fees were not adjusted and represent actual charges, but amounted to less than 17% of total charges.
Statistical methods
Patients were analyzed in the group in which they initiated their treatment. Thus, three patients who initially opted for inpatient management, who subsequently agreed to early discharge, were analyzed in the inpatient group even though their length of stay was only half of other inpatients. Data was analyzed using Statistical Packages for Social Sciences (SPSS) and EpiInfo. Mean comparisons were made using analysis of variance for the three treatment groups and independent two-sided t-tests for two-way comparisons, using an alpha error of 0.05. Analysis of co-variance were used for adjusted mean comparisons. Non-normally distributed data were analyzed using Kruskal-Wallis tests. Proportion comparisons were made by 2 and Fisher's exact tests. Logrank survival analysis was conducted to examine differences in length of survival by treatment group.
Results
Ninety-four consecutive patients receiving high-dose chemotherapy and autologous stem cell rescue were enrolled in this study. No patient was excluded from the analysis nor was any patient excluded from either of the outpatient programs based upon the pretreatment performance status. Complete financial data was available on all patients during the study period. Table 1 shows the patient characteristics for each of the patients treated in the three treatment settings: inpatient, subtotal outpatient, total outpatient. No significant differences were seen with regard to Karnofsky performance status (KPS), diagnosis and age. Borderline statistically significant differences were seen with regard to numbers of prior cycles of chemotherapy and pre-transplant albumin, but these are not considered clinically significant. Hospital length of stay for the three treatment settings is shown in Table 2 . These data include all re-admissions.
Because the toxicities encountered during high-dose chemotherapy and stem cell rescue could significantly impact on the costs and charges of the procedure, we analyzed the incidence of complications of patients in the three groups. Table 3 indicates there were no statistically significant differences among the three groups of patients with regard to incidence of fever, days on antibiotics, number of transfusions received, duration of neutropenia or incidence of life-threatening toxicity. Table 4 shows the comparison of charges and costs for all patients treated in the three treatment settings. There were statistically significant differences with regard to both mean charges and mean costs in the three treatment settings, with the lowest charges and costs being seen in the total outpatient transplant setting, despite the fact that the individual with the single highest overall charge and length of stay was in the total outpatient transplant program. Units of service analysis showed significantly less utilization in the outpatient program for laboratory and pharmacy as well as for room and board charges.
Further analysis of this data shows that for patients with a KPS of 60% or 70% at the time of treatment, there were no statistically significant differences in mean treatment costs for therapy by treatment group even when therapy was originated in the outpatient program (Table 5 ). For patients with a KPS greater than 70%, there were statistically significant and clinically significant differences in treatment costs. Mean inpatient costs were $36 199 as compared to $32 292 for partial outpatient and $24 030 for total outpatient treatment patients (P Ͻ 0.001).
There were no statistically significant differences in response rates or disease-free survival between patients treated in the three treatment groups.
Discussion
High-dose chemotherapy with autologous stem cell rescue has been shown to be of benefit in a variety of disease settings [11] [12] [13] and appears promising in several other areas. However, the high cost of this therapy has proven to be a significant barrier to more widespread use of the treatment and to completing pilot trials in novel areas. A major factor in the high cost of the therapy is the long duration of inpatient hospitalization. We and others have attempted to shift the focus of care to the outpatient setting where costs are generally less. The lower charges for outpatient care is in part a consequence of the method in which costs are allocated in the current health care system. It has been our hope that as the cost of the procedure declines, so too would the barriers to appropriate application of this treatment. Previously, we and others have demonstrated that high-dose chemotherapy in the outpatient setting is feasible and safe and results in substantial reduction in hospital length of stay. 5, 7, 14 The current data show for the first time that substantial reductions in hospital charges and costs are seen when treatment is rendered in this setting.
Patients enrolled in this study were not randomly assigned to a treatment setting. Rather, they were allowed to choose their own treatment setting based upon personal issues such as availability of a caregiver. Randomization would have been problematic since it would have been inappropriate to require patients who wanted to be out of the hospital to be inpatients, or require patients who did not feel comfortable in the outpatient setting to be treated there. This design allows for potential self-selection bias wherein patients who were more ill sought inpatient care, although neither pre-treatment characteristics nor posttreatment side-effects show evidence of this bias. Sixteen of the 20 patients choosing the inpatient program did so stating that they did not have a 'caregiver' available to help Toxicities were defined as one or more toxicity scores greater than or equal to grade 3 using the CALGB Common Toxicity Criteria. monitor their care, which was a requirement of the outpatient program. The other four patients stated that they 'did not feel comfortable' with an outpatient treatment regimen.
Since regimen-related toxicity and costs are closely related, we examined the actual experience of patients in three treatment groups with respect to incidence of fevers, duration of antibiotics, number of transfusions, duration of neutropenia and incidence of grade IV and V toxicities, using the CALGB toxicity criteria. No significant differences were seen among the three groups suggesting that self-selection bias was not a major factor.
Patients were analyzed in their original assignment groups; thus, the four patients originally assigned to the inpatient group but who subsequently asked to be discharged to the outpatient program early, were analyzed in the original inpatient group as assigned, even though this tended to bias the result towards the null hypothesis, namely that there are no differences in cost, between the treatment settings. We also included in our analysis the standardized costs for pre-transplant central venous catheter placement, mobilization of autologous progenitor cells, leukapheresis and cryopreservation, believing these to be essential components of the transplant process. The 931  Table 4 Comparison of charges and costs (in US dollars) for all patients inclusion of these costs which were standardized for all groups also tended to bias the results toward the null hypothesis by diluting out the differences seen during the actual treatment. Analysis of KPS and cost show that the biggest cost savings occur in the majority of patients with a KPS of 80-100%. However, even when patients with a lower KPS (60% or 70%) are treated in the outpatient setting, total costs are only minimally higher than for higher KPS patients treated as inpatients.
In the United States the common mechanism for payment for medical services allows the distinction between an institution's cost and their charges to third party payers, such as government or private insurance agencies. The difference between what it cost the hospital to actually deliver a service or medication and what it charges the third-party payer for this service is known as the cost to charge ratio. The differences between the costs and charges reflect direct and indirect overheads, such as energy expenses and non-medical personnel expenses, as well as profit or margin, depending upon whether the institution is for profit or not for profit. In the United States the Medicare program administered by the federal government analyzes data from each hospital regarding their cost of providing medical services and allows a certain cost to charge ratio depending on the cost center, such as pharmacy, laboratory, radiology, etc. These ratios are institution specific. For this reason we analyze the data both for actual charges as well as calcu- Table 5 Mean treatment cost for high-dose chemotherapy and autologous stem cell rescue by treatment group and Karnofsky performance status (mean costs Ϯ standard deviation)
Inpatient
Partial outpatient Our findings regarding the actual cost of HDC/ASCR are similar to those in a recent study by Smith et al. 3 In that study, patients with Hodgkin's disease or non-Hodgkin's lymphoma, received the BEAM chemotherapy regimen (carmustine, etoposide, cytosine arabinoside and melphalan) followed by either autologous bone marrow or peripheral blood progenitor cells. For those patients receiving peripheral blood progenitor cells, the time to platelet recovery and neutrophil recovery were 16 and 11 days, respectively, similar to our own data. Furthermore, the mean duration of hospitalization of 17 days is identical to our own findings of 17 days for inpatients. Their calculation of actual costs of an inpatient transplant based on prospective determination of resource utilization, was $45 792 if the therapy had been given at the Massey Cancer Center in Virginia, similar to our own findings of $39 703 for this group.
It is important to note that there may be limitations in applying these data to other transplant programs where caregivers may not be so readily available, outpatient housing may be more expensive or less available and the chemotherapy may be more toxic and require more frequent readmissions. Alternatively, it could be argued that more morbid preparative regimens have not been shown to have greater antineoplastic effects compared with regimens which allow outpatient care. 15 Although cost should not be the only determinant in selecting a high-dose chemotherapy regimen, it should be an important factor given the large number of patients who are candidates for this therapy, and the economic impact on health care expenditures.
The large number of patients with a caregiver available (83%) 7 indicates a strong motivation of patients and their families towards outpatient care. We found that these programs were very popular with patients and their families who were willing to undergo considerable disruption and inconvenience to allow treatment to proceed in an outpatient setting. Whether this would be equally true in other localities is difficult to determine, although caregiver availability was not a limiting factor in the study from the Duke University Bone Marrow Transplant Program. 5 This study did not attempt to assess the financial or psychological burden on families and caregivers of patients who are undergoing high-dose chemotherapy in the different treatment settings. This would require a trial utilizing the appropriate tools to measure financial and psychological caregiver burden. A follow-up prospective trial evaluating these parameters is ongoing.
While these data should not be used to coerce reluctant individual patients to undergo their therapy in the outpatient setting, it does demonstrate what is achievable when patients and families are able to participate in their own care in this fashion.
In view of the reduced costs associated with this method of transplantation, it would seem that older calculations of 'value' or costs per year of life saved associated with highdose chemotherapy should be re-examined. Such calculations have been performed frequently to compare the cost and value of high-dose chemotherapy to other medical interventions and treatments. It should be clear that such comparisons and health policy decisions made from such comparisons should be based upon the most current and cost-effective transplant practices.
In summary, outpatient settings for HDC/ASCR reduce the charges and costs associated with this therapy.
